CR10128A - Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4 - Google Patents

Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4

Info

Publication number
CR10128A
CR10128A CR10128A CR10128A CR10128A CR 10128 A CR10128 A CR 10128A CR 10128 A CR10128 A CR 10128A CR 10128 A CR10128 A CR 10128A CR 10128 A CR10128 A CR 10128A
Authority
CR
Costa Rica
Prior art keywords
antibodies
methods
dickkopf
compositions
target
Prior art date
Application number
CR10128A
Other languages
English (en)
Inventor
Shulok Janinie
Cong Feng
Fishman Mark
Ettenberg Seth
Bardroff Michael
Donzeau Mariel
Urlinger Stefanie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10128A publication Critical patent/CR10128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos que se enlazan con el objetivo de proteína Dickkopf (DKK1), así como métodos de uso y kits, para el tratamiento de una célula objetivo, en particular una célula asociada con una condición osteolítica.
CR10128A 2006-01-13 2008-07-04 Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4 CR10128A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75921606P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
CR10128A true CR10128A (es) 2008-08-25

Family

ID=38288117

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10128A CR10128A (es) 2006-01-13 2008-07-04 Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4

Country Status (31)

Country Link
US (3) US8673306B2 (es)
EP (1) EP1976594B1 (es)
JP (2) JP5552233B2 (es)
KR (1) KR101413785B1 (es)
CN (1) CN101400406B (es)
AR (1) AR060017A1 (es)
AU (1) AU2007207787B2 (es)
BR (1) BRPI0706524A2 (es)
CA (1) CA2636579A1 (es)
CR (1) CR10128A (es)
CU (1) CU23871B1 (es)
EA (1) EA015538B1 (es)
EC (1) ECSP088618A (es)
GE (1) GEP20125476B (es)
HK (1) HK1121420A1 (es)
HN (1) HN2008001104A (es)
IL (1) IL192631A (es)
MA (1) MA30158B1 (es)
ME (2) ME00010B (es)
MY (1) MY153573A (es)
NO (1) NO20083477L (es)
NZ (1) NZ569555A (es)
PE (2) PE20120816A1 (es)
SG (1) SG169327A1 (es)
SM (1) SMP200800042B (es)
SV (1) SV2008002980A (es)
TN (1) TNSN08297A1 (es)
TW (1) TWI432450B (es)
UA (1) UA101944C2 (es)
WO (1) WO2007084344A2 (es)
ZA (1) ZA200805743B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
KR20110117601A (ko) * 2010-04-21 2011-10-27 주식회사 테라젠이텍스 혈관신생과 연관된 화합물을 탐색하는 방법
US8450274B2 (en) 2006-05-24 2013-05-28 Theragenetex Co., Ltd. DKK2 protein and use thereof
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
JP5320730B2 (ja) * 2007-12-26 2013-10-23 Ｊｎｃ株式会社 発光基質水溶液およびその製造方法
WO2010037041A2 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
US20120052070A1 (en) * 2009-05-07 2012-03-01 Novartis Ag Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
JP2012526542A (ja) 2009-05-12 2012-11-01 ファイザー・インク 遮断抗ｄｋｋ−１抗体およびその使用
WO2010130832A2 (en) * 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
SA111320266B1 (ar) * 2010-03-11 2015-06-21 رينات نيوروساينس كوربوريشن أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2632951B1 (en) * 2010-10-27 2017-08-02 Amgen Inc. Dkk1 antibodies and methods of use
EP2670435B1 (en) * 2011-02-01 2017-08-23 The University of Hong Kong Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
CN103487581A (zh) * 2012-06-08 2014-01-01 上海市肿瘤研究所 血清dkk1在制备甲胎蛋白阴性肝细胞癌的诊断试剂中的用途
CN103472226A (zh) * 2012-06-08 2013-12-25 上海市肿瘤研究所 血清dkk1在制备早期肝细胞癌或小肝细胞癌的诊断试剂中的用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP2016510411A (ja) * 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
CN103083686B (zh) * 2013-02-18 2014-09-10 上海交通大学医学院附属仁济医院 Dkk4基因及其编码蛋白在制备药物中的应用
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US10398765B2 (en) 2014-07-03 2019-09-03 Yale University Dickkopf2 (Dkk2) inhibition suppresses tumor formation
DE102016206820B4 (de) 2015-04-22 2017-07-27 BSH Hausgeräte GmbH Weiterentwicklung eines Induktionswasserkochers, einer Kaffeemaschine und einer Suppenmaschine
CN117964732A (zh) * 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
CN105203773A (zh) * 2015-09-28 2015-12-30 成都博奥新景医学科技有限公司 一种人Dickkopf-1蛋白（DKK-1）定量检测试剂盒
RU2018119317A (ru) * 2015-10-28 2019-12-04 Йейл Юниверсити Гуманизированное антитело к dkk2 и его применение
RU2656160C2 (ru) 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
EP3532099A1 (en) 2016-10-26 2019-09-04 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
WO2018208108A1 (ko) * 2017-05-10 2018-11-15 주식회사 굳티셀 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도
US20220088051A1 (en) * 2019-01-15 2022-03-24 Bioneer Corporation Double-stranded oligonucleotide targeting dkk1 gene, construct including same, and hair loss prevention or hair growth composition containing same
US20220089707A1 (en) * 2019-02-01 2022-03-24 Board Of Regents, The University Of Texas System Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof
MA56045A (fr) 2019-05-31 2022-04-06 Alx Oncology Inc Méthodes de traitement du cancer avec une protéine de fusion sirpalpha-fc en association avec un inhibiteur de point de contrôle immunitaire
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CN111632147A (zh) * 2020-06-07 2020-09-08 重庆医科大学 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
WO2022140670A2 (en) * 2020-12-23 2022-06-30 Phenomic Ai Anti-activin antibodies and methods of using the same
WO2023046147A1 (zh) * 2021-09-26 2023-03-30 安沛治疗有限公司 针对dkk1的适体及其用途
WO2023143444A1 (zh) * 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP2001524824A (ja) 1997-04-16 2001-12-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド Ｃｒｓｐタンパク質（システインに富む分泌性タンパク質）、それらをコードする核酸分子およびその用途
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AU5233599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
US7098312B2 (en) * 1998-09-01 2006-08-29 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
DZ3494A1 (fr) 2001-01-05 2002-07-11 Pfizer Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
KR20030087001A (ko) * 2001-02-16 2003-11-12 제넨테크, 인크. Ｄｋｋ－１ 또는 그의 길항제가 관련된 치료법
US7091323B2 (en) 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
AU2002359357A1 (en) 2001-11-07 2003-07-09 The Board Of Trustees Of The University Of Arkansas Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
ES2362681T3 (es) 2002-12-05 2011-07-11 The Board Of Trustees Of The University Of Arkansas Determinantes moleculares de la osteopatía por mieloma y uso de los mismos.
US20050084494A1 (en) 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7709611B2 (en) * 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR20070114324A (ko) * 2005-03-25 2007-11-30 글리카트 바이오테크놀로지 아게 Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
US8716195B2 (en) * 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening

Also Published As

Publication number Publication date
NO20083477L (no) 2008-10-13
AU2007207787A1 (en) 2007-07-26
AR060017A1 (es) 2008-05-21
CA2636579A1 (en) 2007-07-26
SV2008002980A (es) 2010-05-21
ZA200805743B (en) 2009-08-26
PE20071239A1 (es) 2008-02-12
GEP20125476B (en) 2012-04-25
JP2013099334A (ja) 2013-05-23
BRPI0706524A2 (pt) 2011-03-29
TWI432450B (zh) 2014-04-01
US9296813B2 (en) 2016-03-29
HN2008001104A (es) 2011-06-08
EP1976594B1 (en) 2015-05-06
KR101413785B1 (ko) 2014-07-09
SMAP200800042A (it) 2008-07-30
CN101400406A (zh) 2009-04-01
MEP1308A (xx) 2010-02-10
TW200804417A (en) 2008-01-16
WO2007084344A2 (en) 2007-07-26
JP5552233B2 (ja) 2014-07-16
JP2009523421A (ja) 2009-06-25
EA015538B1 (ru) 2011-08-30
CN101400406B (zh) 2014-01-29
MY153573A (en) 2015-02-27
EA200801679A1 (ru) 2009-02-27
KR20080085908A (ko) 2008-09-24
ECSP088618A (es) 2008-08-29
HK1121420A1 (en) 2009-04-24
WO2007084344A3 (en) 2008-02-14
US20140341901A1 (en) 2014-11-20
ME00010B (me) 2010-06-10
US8673306B2 (en) 2014-03-18
CU23871B1 (es) 2013-03-27
PE20120816A1 (es) 2012-08-01
US20140170147A1 (en) 2014-06-19
CU20080133A7 (es) 2012-06-21
IL192631A (en) 2015-06-30
NZ569555A (en) 2011-12-22
AU2007207787B2 (en) 2011-03-17
SMP200800042B (it) 2009-07-14
MA30158B1 (fr) 2009-01-02
EP1976594A2 (en) 2008-10-08
IL192631A0 (en) 2011-08-01
SG169327A1 (en) 2011-03-30
US20120023600A1 (en) 2012-01-26
UA101944C2 (ru) 2013-05-27
TNSN08297A1 (en) 2009-12-29

Similar Documents

Publication Publication Date Title
CR10128A (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
CO6410314A2 (es) Proteínas de unión a il-17
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6680656A2 (es) Anticuerpos para metaloproteinasa -9 de matriz
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
AU2016204344A1 (en) Improved methods and compositions for wound healing
CR20120581A (es) Proteínas de unión a il-1
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
HN2005029978A (es) Formulaciones
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EA201000864A1 (ru) Фенилоксетанильные производные
BRPI0802428A2 (pt) uso de óxidos, e, composição para tratamento de superfìcie
DOP2010000336A (es) Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin
BRPI0907469B8 (pt) composição farmacêutica
BRPI0504469B8 (pt) composições cicatrizantes
CY1116623T1 (el) Συνθεσεις και μεθοδοι για αντισωματα κατα της πρωτεϊνης c5 συμπληρωματος